⚕ GalenOps field
←

SITE002-0237

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2022-11-27

AEs
7
Serious
1
Dropout signal
–

Adverse events

severe assessed

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-01 (study day 15); relationship: not assessed

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-18 (study day 32); relationship: not assessed

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-04-21 (study day 125); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-06-19 (study day 184); relationship: not assessed

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-17 (study day 396); relationship: N

severe serious assessed

Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-01-20 (study day 399); relationship: not assessed; serious criteria: life-threatening

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-11 (study day 421); relationship: not assessed

Data queries

No data queries.